GleamWall
中文EN

SSII SS Innovations International, Inc.

Surgical & Medical Instruments & Apparatus · Nasdaq · SEC CIK 1676163 · Fiscal year ends 12/31

Financial factors as of 2026-09-30 (2026Q3), TTM = sum of the last four quarters

Growth

TTM revenue YoY27.3%
TTM net income YoY15.5%
TTM EPS YoY-16.7%
Revenue 3-yr CAGR104.7%
Net income 3-yr CAGR—

Margins

Gross margin47.7%
Operating margin-27.7%
Net margin-31.5%
FCF margin—
EBITDA margin-24.8%

Returns

ROE-32.3%
ROA-17.4%
ROIC (approx.)-28.4%
Asset turnover0.55x

Leverage & solvency

Liabilities / assets48.3%
Debt / equity0.03x
Current ratio2.10x
Interest coverage-8.95x

Cash quality & payout

Operating cash flow / net income1.00x
Accruals ratio-0.0%
Payout ratio—
Capex / revenue—

Factor history charts and full statement history on Pro 🔒

Financial statements

Line item FY20252025-12-31FY20242024-12-31FY20232023-12-31FY20222022-12-31FY20212021-12-31
Income statement
Revenue$42.48M$20.65M$5.88M$1.44M—
Cost of revenue$22.94M$12.20M$5.15M$1.38M—
Gross profit$19.54M$8.45M$725,528$60,577—
R&D expense$3.69M$2.49M$1.06M$987,443$1,000
SG&A expense$14.85M$10.16M$10.06M$1.94M$458,801
Operating income-$8.19M-$18.98M-$20.27M-$2.96M—
Interest expense$1.11M$973,235$894,621$265,522—
Pretax income-$8.16M-$19.15M-$20.88M-$3.21M-$1.48M
Income tax$3.97M————
Net income-$12.13M-$19.15M-$20.88M-$3.21M-$1.48M
EBITDA-$7.12M-$18.54M-$20.12M-$2.86M—
EPS (basic)-0.06-0.11-0.14-0.03-0.05
EPS (diluted)-0.06-0.11-0.14-0.03-0.05
Weighted avg. shares (diluted)198.70M181.20M152.07M128.16M28.48M
Banking
Net interest income$497,549$335,222$151,497$2,994—
Deposits——$4.96M——
Balance sheet
Cash & equivalents$3.21M$6.62M$7.09M$274,625$87,709
Receivables$12.40M$4.47M$1.90M$156,857—
Inventory$17.06M$10.21M$7.02M$904,103—
Current assets$48.77M$27.42M$21.43M$4.10M$408,065
PP&E, net$9.10M$5.39M$706,405$417,014$20,542
Total assets$74.23M$42.39M$31.52M$6.98M$428,607
Current liabilities$26.24M$21.33M$8.47M$7.77M$287,281
Short-term debt$11.44M—$510,189$120,880—
Long-term debt——$510,189$469,017—
Total debt——$1.02M$589,897—
Total liabilities$36.01M$28.93M$11.80M$9.66M-$157,004
Shareholders' equity$38.22M$13.46M$19.72M-$2.68M$585,611
Net debt——-$6.07M$315,272—
Shares outstanding194.17M171.58M170.71M128.16M37.85M
Cash flow statement
Operating cash flow-$18.54M-$9.50M-$15.36M-$5.99M-$363,034
Capital expenditure$3.66M$661,479$453,327$220,324—
Free cash flow-$22.20M-$10.16M-$15.81M-$6.21M—
Investing cash flow-$3.66M-$661,479-$453,327$240,818$38,150
Financing cash flow$26.17M$9.43M$22.80M$5.90M$569,949
Depreciation & amortization$1.08M$436,005$152,738$96,577$18,787
Stock-based compensation$8.13M$14.34M$9.72M$865,468$767,237
Share buybacks————$26,000

Free plan shows the latest 5 periods; Pro shows all 10 🔒

· No price-based ratios such as P/E or P/B (the site uses no licensed market data). Blanks are shown as —.

Source: SEC EDGAR XBRL (financial statements filed with the SEC), updated 2026-11-18 06:30.